Common community-acquired infections and subsequent risk of multiple myeloma: A population-based study

International Journal of Cancer

Volumn 134, Issue 7, 2014, Pages 1734-1740

  McShane, Charlene M ^a   Murray, Liam J ^a   Engels, Eric A ^b   Landgren, Ola ^b   Anderson, Lesley A ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

herpes zoster; infections; multiple myeloma; respiratory tract infections

Indexed keywords

AGE DISTRIBUTION; AGED; ARTICLE; BRONCHITIS; CANCER RISK; CELLULITIS; COLD; COMMUNICABLE DISEASE; CONTROLLED STUDY; CYSTITIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FEMALE; GASTROENTERITIS; GINGIVITIS; HERPES ZOSTER; HUMAN; INFLUENZA; LARYNGITIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PATHOGENESIS; PHARYNGITIS; PNEUMONIA; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATITIS; PYELONEPHRITIS; SEX DIFFERENCE; SINUSITIS;

HERPES ZOSTER; INFECTIONS; MULTIPLE MYELOMA; RESPIRATORY TRACT INFECTIONS;

AGED; AGED, 80 AND OVER; COMMUNITY-ACQUIRED INFECTIONS; CONFIDENCE INTERVALS; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; ODDS RATIO; RISK; SEER PROGRAM; UNITED STATES;

EID: 84892614368     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28479     Document Type: Article

References (45)

1. Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005; 23: 9219-26.
2. Murakami H, Hayashi K, Hatsumi N, et al. Risk factors for early death in patients undergoing treatment for multiple myeloma. Ann Hematol 2001; 80: 452-5.
3. Nucci M, Anaissie E,. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009; 49: 1211-25.
4. Twomey J,. Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch Intern Med 1973; 132: 562-65.
5. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-57.
6. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412-7.
7. Weiss BM, Abadie J, Verma P, et al. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113: 5418-22.
8. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. New Engl J Med 2002; 346: 564-9.
9. Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 2010; 116: 5501-6.
10. Gavazzi G, Krause K-H,. Ageing and infection. Lancet Infect Dis 2002; 2: 659-66.
11. Karlsson J, Andréasson B, Kondori N, et al. Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance. Clin Vaccine Immunol 2011; 18: 969-77.
12. Mantovani A, Allavena P, Sica A, Balkwill F,. Cancer-related inflammation. Nature 2008; 454: 436-44.
13. Brown LM, Gridley G, Check D, et al. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among White and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 2008; 111: 3388-94.
14. Lindqvist EK, Goldin LR, Landgren O, et al. Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood 2011; 118: 6284-91.
15. Doody MM, Linet MS, Glass AG, et al. Leukemia, lymphoma, and multiple myeloma following selected medical conditions. Cancer Causes Control 1992; 3: 449-56.
16. Nanni O, Falcini F, Buiatti E, et al. Multiple Myeloma and Work in Agriculture: results of a Case-Control Study in Forlì, Italy. Cancer Causes Control 9: 277-83.
17. Landgren O, Rapkin JS, Mellemkjaer L, et al. Respiratory tract infections in the pathway to multiple myeloma: a population-based study in Scandinavia. Haematologica 91: 1697-1700.
18. Gramenzi A, Buttino I, D'Avanzo B, et al. Medical history and the risk of multiple myeloma. Br J Cancer 1991; 63: 769-72.
19. Vineis P, Crosignani P, Sacerdote C, et al. Haematopoietic cancer and medical history: a multicentre case control study. J Epidemiol Commun Health 2000; 54: 431-6.
20. Anderson LA, Pfeiffer R, Warren JL, et al. Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev 2008; 17: 3069-75.
21. Overview of the SEER Program. Available at: http://seer.cancer.gov/about/ overview.html.
22. Engels EA, Pfeiffer RM, Ricker W, et al. Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly. Am J Epidemiol 2011; 174: 860-70.
23. Warren JL, Klabunde CN, Schrag D, et al. Overview of SEER-Medicare Data. Content, research applications, and generalizability to the United States elderly population. Med Care 2002; 40: IV-3-IV-18.
24. Gornick ME, Warren JL, Eggers PW, et al. Thirty years of Medicare: impact on the covered population. Health Care Financ R 1996; 18: 179-237.
25. Potosky AL, Riley GF, Lubitz JD, et al. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993; 31: 732-48.
26. Quinlan SC, Morton LM, Pfeiffer RM, et al. Increased risk for lymphoid and myeloid neoplasms in elderly solid-organ transplant recipients. Cancer Epidemiol Biomarkers Prev 2010; 19: 1229-37.
27. Gregersen H, Pedersen G, Svendsen N, et al. Multiple myeloma following an episode of community-acquired pneumococcal bacteraemia or meningitis. APMIS 2001; 109: 797-800.
28. Kristinsson SY, Tang M, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica 2012; 97: 854-8.
29. Gregersen H, Madsen KM, Sørensen HT, et al. The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance. Eur J Haematol 1998; 61: 140-4.
30. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proc 2003; 78: 21-33.
31. Cheson BD, Walker HS, Heath ME, et al. Defective binding of the third component of complement (C3) to Streptococcus pneumoniae in multiple myeloma. Blood 1984; 63: 949-57.
32. Sørensen HT, Olsen JH, Jepsen P, et al. The risk and prognosis of cancer after hospitalisation for herpes zoster: a population-based follow-up study. Br J Cancer 2004; 91: 1275-9.
33. Tavani A, La Vecchia C, Franceschi S, et al. Medical history and risk of Hodgkin's and non-Hodgkin's lymphomas. Eur J Cancer Prev 2000; 9: 59-64.
34. Anderson LA, Landgren O, Engels EA,. Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia. Brit J Haematol 2009; 147: 444-9.
35. Arvin A,. Varicella-zoster virus. Clin Microbiol Rev 1996; 9: 361.
36. Amanna IJ, Carlson NE, Slifka MK,. Duration of humoral immunity to common viral and vaccine antigens. New Engl J Med 2007; 357: 1903-15.
37. Engels EA, Rosenberg P, Biggar R,. Zoster incidence in human immunodeficiency virus-infected hemophiliacs and homosexual men, 1984-1997. J Infect Dis 1999; 180: 1784-9.
38. Grulich AE, Van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67.
39. Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002; 99: 2185-91.
40. Avet-Loiseau H, Facon T, Daviet A, et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Cancer Res 1999: 4546-50.
41. Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002; 100: 1417-24.
42. Bida JP, Kyle RA, Therneau TM, et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clinic Proc Mayo Clinic 2009; 84: 685-93.
43. Costa DB, Shin B, Cooper DL,. Pneumococcemia as the presenting feature of multiple myeloma. Am J Haematol 2004; 77: 277-81.
44. Kalambokis GN, Christou L, Tsianos EV,. Multiple myeloma presenting with an acute bacterial infection. Int J Hematol 2009; 31: 375-83.
45. Thomas SL, Wheeler JG, Hall AJ,. Micronutrient intake and the risk of herpes zoster: a case-control study. Int J Epidemiol 2006; 35: 307-14.